Praxis Precision Medicines (NASDAQ:PRAX) Given Buy Rating at Truist Financial

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Truist Financial in a report released on Thursday, Benzinga reports. They currently have a $150.00 target price on the stock. Truist Financial’s target price suggests a potential upside of 233.70% from the stock’s current price. PRAX has been […]

Related Keywords

Robertw Baird , ,Jump Financial ,Citigroup Inc ,Jefferies Financial Group ,Praxis Precision Medicines Inc ,Praxis Precision Medicines Company Profile ,York Mellon Corp ,Connor Clark Lunn Investment Management Ltd ,Simplex Trading ,Praxis Precision Medicines ,Get Free Report ,Truist Financial ,Financial Group ,Precision Medicines ,Lunn Investment Management ,New York Mellon Corp ,Praxis Precision Medicines Daily ,